



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	300714	Orthoplex Intestaclear
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Bio Concepts Pty Ltd	
<b>Postal Address</b>	PO Box 190, Banyo, Brisbane, QLD, 4014 Australia	
<b>ARTG Start Date</b>	13/03/2018	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

The warning statement 'Do not use if pregnant or likely to become pregnant' must be displayed on the medicine label.

### Products

#### 1 . Orthoplex Intestaclear

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	4/02/2021
---------------------	-------------------------	-----------------------	-----------

#### Permitted Indications

Maintain/support general health and wellbeing  
Traditionally used in Western herbal medicine to maintain/support digestive system health

#### Indication Requirements

No Indication Requirements included on Record

#### Standard Indications

No Standard Indications included on Record

#### Specific Indications

No Specific Indications included on Record

#### Warnings

Not for prolonged use. May harm liver.  
If symptoms persist, seek the advice of a healthcare professional.

#### Additional Product information

#### Pack Size/Poison information

<b>Pack Size</b>	<b>Poison Schedule</b>
------------------	------------------------

#### Components

##### 1 . Formulation 1

<b>Dosage Form</b>	Capsule, hard
<b>Route of Administration</b>	Oral

#### Visual Identification

#### Active Ingredients

Public Summary



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

<b>Allium sativum bulb Extract dry concentrate</b>	<b>14.4 mg</b>
Equivalent: Allium sativum (Dry)	720 mg
<b>Artemisia annua herb Extract dry concentrate</b>	<b>40 mg</b>
Equivalent: Artemisia annua (Dry)	400 mg
<b>Berberis vulgaris stem bark Extract dry concentrate standardised</b>	<b>36 mg</b>
Equivalent: Berberis vulgaris (Dry)	360 mg
<b>Clove Bud Oil</b>	<b>50 mg</b>
<b>Handroanthus impetiginosus stem bark inner Extract dry concentrate</b>	<b>20 mg</b>
Equivalent: Handroanthus impetiginosus (Dry)	200 mg
<b>Juglans nigra fruit hull Extract dry concentrate</b>	<b>40 mg</b>
Equivalent: Juglans nigra (Dry)	400 mg
<b>Origanum Oil Spanish</b>	<b>50 mg</b>
<b>Thyme Oil</b>	<b>50 mg</b>

**Other Ingredients (Excipients)**

ascorbyl palmitate  
calcium hydrogen phosphate dihydrate  
colloidal anhydrous silica  
gellan gum  
hypromellose  
microcrystalline cellulose

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary